KH-901

特异性溶瘤重组腺病毒

Report date: 2022/05/17 17:50:49

Base Information

Drug NameKH-901
Drug Alias Name特异性溶瘤重组腺病毒（康弘药业）Specific oncolytic adenovirus (Kanghong Pharmaceutical)KH-901
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor stimulantsApoptosis stimulants
TargetsGranulocyte-macrophage colony-stimulating factor receptor
Therapy Area/IndicationsHead and Neck Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChengdu Kanghong Biotechnologies Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengdu Phargentech Technology Co Ltd
Inactive CompaniesChengdu Kanghong Biotechnologies Co Ltd
Active IndicationsHead and Neck Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A